8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  March 17, 2008

BRUKER CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation) 000-30833
(Commission
File Number) 04-3110160
(IRS Employer
Identification No.)

40 Manning Road
Billerica, MA 01821
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (978) 663-3660

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the reporting obligation of the registrant under any of the following provisions:
o	Written communications pursuant to Rule 425 under the Securities Act
o	Soliciting material pursuant to Rule 14a-12 of the Exchange Act
o	Pre-commencement communications pursuant to Rule 14d-2(b) Exchange Act
o	Pre-commencement communications pursuant to Rule 13e-4(c) Exchange Act

Section 2 — Financial Information

Item 2.02.  Results of Operations and Financial Condition

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of  Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On March 17, 2008, Bruker Corporation issued a press release announcing combined financial results as of and for the three and twelve months ended December 31, 2007, including the results of the Bruker BioSpin Group acquired on February 26, 2008.  A copy of the press release is attached hereto as Exhibit 99.1.

2

Section 9 — Financial Statements and Exhibits

Item 9.01.  Financial Statements and Exhibits.

             (d)              Exhibits

Number
99.1	Press release dated March 17, 2008.

3

SIGNATURES

                Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRUKER CORPORATION
	(Registrant)
Date: March 17, 2008	By:	/s/Frank H. Laukien
		Frank H. Laukien, Ph.D.
		Chief Executive Officer and President

4

Exhibit Index

Exhibit  Number	Exhibit Name	Location
99.1	Press release dated March 17, 2008.	Furnished herewith*

*Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

5

EX-99.1

Exhibit 99.1

Bruker Corporation Reports its Combined Financial Results for the Fourth Quarter and Year 2007, Including the Bruker BioSpin Group

Including the Recently Acquired Bruker BioSpin Group, the Combined Company in 2007 had Revenue of $1.03 Billion, Net Income of $97 Million, EPS of $0.59 and Free Cash Flow of $102 Million

BILLERICA, Mass., March 17, 2008 (BUSINESS WIRE)  —  Bruker Corporation (NASDAQ: BRKR) today reported financial results for the fourth quarter and year ended December 31, 2007, now including the results of the Bruker BioSpin Group.

On February 26, 2008, Bruker BioSciences Corporation closed its acquisition of the Bruker BioSpin Group, and renamed itself Bruker Corporation.  Under US GAAP, this transaction is accounted for as an acquisition of businesses under common control, and as a result all one-time transaction costs are expensed in the period in which they are incurred, rather than being added to goodwill.  In addition, after the closing of the transaction all historical consolidated balance sheets, statements of operations, statements of cash flows and notes to the consolidated financial statements in future filings with the Securities and Exchange Commission will be restated by combining the historical consolidated financial statements of Bruker Corporation with those of the Bruker BioSpin Group.  The information contained herein will discuss the combined financial results of Bruker Corporation, as it legally exists since the closing on February 26, 2008, and which now include the financial results of the Bruker BioSpin Group (“Combined”).  These will be compared in some categories to the historical, standalone financial results of Bruker BioSciences Corporation, as it legally existed on December 31, 2007 (“Standalone”).

Combined Financial Results of Bruker Corporation

In the fourth quarter of 2007, Combined revenue increased by 31% to $343.1 million, compared to Combined revenue of $261.5 million in the fourth quarter of 2006.  Excluding the effects of foreign currency translation, Combined fourth quarter 2007 revenue increased by 22% year-over-year.  Combined fourth quarter 2007 revenue of $343.1 million was 87% higher than Standalone fourth quarter 2007 revenue of $183.7 million, as previously reported by Bruker BioSciences Corporation.

Combined net income in the fourth quarter of 2007 increased to $37.0 million, or $0.22 per diluted share, compared to Combined net income of $35.6 million, or $0.22 per diluted share, in the fourth quarter of 2006.  Included in Combined GAAP net income for the fourth quarter of 2007 were after-tax charges of $6.9 million, or $0.04 per diluted share, for expenses related to the acquisition of the Bruker BioSpin Group.

Combined fourth quarter 2007 net income of $37.0 million was 164% higher than Standalone fourth quarter 2007 net income of $14.0 million, as previously reported by Bruker BioSciences Corporation.  Combined fourth quarter 2007 earnings per diluted share of $0.22 were 69% higher than Standalone fourth quarter 2007 earnings per diluted share of $0.13, as previously reported by Bruker BioSciences Corporation.

For the full year 2007, Combined revenue increased by 21% to $1,032.4 million, compared to Combined revenue of $851.0 million for the full year 2006.  Excluding the effects of foreign currency translation, Combined 2007 revenue increased by 15% year-over-year, including 1% growth from acquisitions, and organic growth of 14%.  Combined 2007 revenue was 89% higher than Standalone 2007 revenue of $547.6 million, as previously reported by Bruker BioSciences Corporation.

Combined net income in 2007 increased 30% to $97.2 million, or $0.59 per diluted share, compared to Combined net income of $74.8 million, or $0.47 per diluted share, in 2006.  Included in Combined GAAP net income for 2007 were after-tax charges of $7.4 million, or $0.05 per diluted share, for expenses related to the acquisition of the Bruker BioSpin Group.  For comparison, included in Combined GAAP net income for the year 2006 were after-tax charges of $5.0 million, or $0.03 per diluted share, for expenses related to the acquisition of Bruker Optics, which was completed on July 1, 2006.

Combined 2007 net income of $97.2 million was 208% higher than the Standalone 2007 net income of $31.5 million, as previously reported by Bruker BioSciences Corporation.  Combined 2007 earnings per diluted share of $0.59 were 97% higher than the Standalone 2007 earnings per diluted share of $0.30, as previously reported by Bruker BioSciences Corporation.

Combined cash flow from operations in 2007 was $127.1 million, compared to $82.8 million in 2006.  Combined free cash flow, defined as operating cash flow less capital expenditures, was $101.8 million during 2007, compared to $61.7 million during 2006.  As of December 31, 2007, the Combined Bruker Corporation had net cash of $290.4 million.

Comment and Outlook

Frank Laukien, President and CEO, commented: “The addition of the Bruker BioSpin Group to Bruker Corporation represents a significant step-up in our combined financial performance.  We are extremely pleased that our overall rapid growth has enabled the Combined Bruker to cross the billion-dollar-revenue threshold already in 2007, with Combined, currency-adjusted 2007 revenue growth of 15%.  Moreover, we have reached new levels of profitability and cash flow with Combined 2007 Bruker net income of $97 million and free cash flow of $102 million.  Our Combined 2007 GAAP EPS of $0.59 was nearly twice the previously reported Standalone 2007 EPS of $0.30 of Bruker BioSciences Corporation.”

Bill Knight, CFO, continued with an outlook for the year 2008: “Our markets in 2007 were strong, yet going forward there is considerable economic uncertainty.  Under the assumption that the overall market conditions we face will not deteriorate significantly, our financial goals for the full year 2008 include:

·revenue growth greater than 8%,

·operating margins greater than 14%, excluding expenses associated with the acquisition of the Bruker BioSpin Group,

·net income margins greater than 9%, excluding expenses associated with the acquisition of the Bruker BioSpin Group, and

·improved balance sheet metrics and operating cash flows.

It should be kept in mind that with the addition of the Bruker BioSpin Group, we expect that quarterly fluctuations in our financial results will increase.”

EARNINGS CONFERENCE CALL

Bruker Corporation will host an operator-assisted earnings conference call at 8 a.m. Eastern Time on Monday, March 17, 2008.  To listen to the webcast, investors can go to www.bruker.com and click on the live web broadcast symbol.  The webcast will be available through the Company web site for 30 days.  Investors can also listen and participate on the telephone in the US and Canada by calling 888-339-2688, or 617-847-3007 outside the US and Canada.  Investors should refer to the Bruker Corporation Earnings Call.  A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or 617-801-6888 outside the US and Canada, and then entering replay pass code 13763010.

ABOUT BRUKER CORPORATION (NASDAQ: BRKR)

As of February 26, 2008, Bruker Corporation has become the parent company of the entire Bruker group of companies.  Bruker Corporation now operates in two segments, the life science and analytical (LSA) systems segment, and the international advanced superconductor (IAS) segment.  For more information, please visit www.bruker.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2006, our most recent quarterly reports on Form 10-Q and  our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Bruker Corporation (including Bruker BioSpin Group)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

	Three  Months Ended December 31,					Twelve Months Ended December 31,
	2007		2006			2007		2006
Product revenue	$	303,875	$	233,845		$	913,238	$	758,532
Service revenue	37,758		25,938			115,419		87,873
Other revenue	1,438		1,762			3,791		4,602
Total revenue	343,071		261,545			1,032,448		851,007
Cost of product revenue	157,207		115,539			489,246		399,182
Cost of service revenue	24,407		15,991			73,591		53,207
Total cost of revenue	181,614		131,530			562,837		452,389
Gross profit margin	161,457		130,015			469,611		398,618
Operating Expenses:
Sales and marketing	45,965		39,069			156,783		131,393
General and administrative	17,165		14,739			59,600		51,853
Research and development	30,289		27,227			110,751		102,611
Acquisition related charges	6,868		(105		)	7,412		5,724
Total operating expenses	100,287		80,930			334,546		291,581
Operating income	61,170		49,085			135,065		107,037
Interest and other income (expense), net	1,206		(1,493		)	5,750		4,716
Income before income tax provision and minority interest in consolidated subsidiaries	62,376		47,592			140,815		111,753
Income tax provision	25,378		12,043			43,278		36,927
Income before minority interest in consolidated subsidiaries	36,998		35,549			97,537		74,826
Minority interest in consolidated subsidiaries	44		(67		)	299		8
Net income	$	36,954	$	35,616		$	97,238	$	74,818
Net income per share:
Basic	$	0.23	$	0.22		$	0.60	$	0.47
Diluted	$	0.22	$	0.22		$	0.59	$	0.47
Weighted average shares outstanding:
Basic	162,053		159,046			161,247		159,057
Diluted	164,725		160,915			164,314		160,106

Bruker Corporation (including Bruker BioSpin Group)

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

	December 31, 2007		December 31, 2006
ASSETS
Current assets:
Cash and short-term investments	$	344,504	$	325,689
Accounts receivable, net	185,217		147,693
Inventories	447,688		408,892
Other current assets	57,288		46,306
Total current assets	1,034,697		928,580
Property and equipment, net	207,588		190,442
Intangible and other assets	69,346		57,558
Total assets	$	1,311,631	$	1,176,580
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Short-term borrowings	$	34,846	$	27,190
Accounts payable	52,293		46,407
Other current liabilities	474,052		430,821
Total current liabilities	561,191		504,418
Long-term debt	6,394		26,995
Other long-term liabilities	107,656		71,648
Minority interest in subsidiaries	538		239
Total shareholders' equity	635,852		573,280
Total liabilities and shareholders' equity	$	1,311,631	$	1,176,580

FOR FURTHER INFORMATION:	Michael Willett, Investor Relations Officer
	Tel: +1 (978) 663-3660, ext. 1411
	Email:michael.willett@bruker.com